Emerging data reveals that retatrutide, a dual-action medication, could represent a major improvement in size loss . This drug combines the properties of a GLP-1 agonist and a GIP analog, seemingly offering a enhanced impact than current approaches . Clinical trials have shown promising findings , including significant decreases in size and gains